Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells

Theranostics

Volumn 5, Issue 7, 2015, Pages 755-771

  Shen, Hongxin ^a   Shi, Sanjun ^a   Zhang, Zhirong ^a   Gong, Tao ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer stem like cell; CD44; Hyaluronic acid; Melanoma; Paclitaxel

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; LIPID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG UPTAKE; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; SIDE POPULATION CELL; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; HUMANS; HYALURONIC ACID; LIPIDS; MELANOMA; MICE; NANOPARTICLES; NEOPLASTIC STEM CELLS; PACLITAXEL;

EID: 84938684191     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10804     Document Type: Article

References (56)

1. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Advanced drug delivery reviews. 2004; 56: 1257-72. doi:10.1016/j.addr.2003.12.002.
2. Lee H, Kim JB, Park SY, Kim S-S, Kim H. Combination Effect of Paclitaxel and Hyaluronic Acid on Cancer Stem-Like Side Population Cells. Journal of Biomedical Nanotechnology. 2013; 9: 299-302. doi:10.1166/jbn.2013.1498.
3. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clinical cancer research. 2010; 16: 3121-9. doi:10.1158/1078-0432.CCR-09-2933.
4. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug resistance updates. 2010; 13: 109-18. doi:10.1016/j.drup.2010.07.001.
5. Wu XD, Chen H, Wang XD. Can lung cancer stem cells be targeted for therapies? Cancer Treat Rev. 2012; 38: 580-8. doi: 10.1016/j.ctrv.2012.02.013.
6. Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cellular & molecular immunology. 2007; 4: 467-72.
7. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Annals of surgical oncology. 2008; 15: 2927-33. doi:10.1245/s10434-008-0074-0.
8. Leung ELH, Fiscus RR, Tung JW, Tin VPC, Cheng LC, Sihoe ADL, et al. Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties. Plos One. 2010; 5. doi:10.1371/journal.pone.0014062.
9. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. P Natl Acad Sci USA. 2009; 106: 268-73. doi: 10.1073/pnas.0810956106.
10. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol. 2009; 1. doi:10.1186/1758-3284-1-27.
11. Su J, Xu XH, Huang QA, Lu MQ, Li DJ, Xue F, et al. Identification of Cancer Stem-like CD44(+) Cells in Human Nasopharyngeal Carcinoma Cell Line. Arch Med Res. 2011; 42: 15-21. doi:10.1016/j.arcmed.2011.01.007.
12. Mine S, Fujisaki T, Kawahara C, Tabata T, Iida T, Yasuda M, et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res. 2003; 288: 189-97.
13. Mimeault M, Batra SK. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol. 2010; 25: 1057-73.
14. Mine S, Fujisaki T, Kawahara C, Tabata T, Iida T, Yasuda M, et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res. 2003; 288: 189-97. doi:10.1016/S0014-4827(03)00184-8.
15. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol. 2007; 83: 332-40. doi: 10.1016/j.yexmp.2007.08.013.
16. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clinical pharmacokinetics. 2013; 52: 83-124. doi:10.1007/s40262-012-0027-4.
17. Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Molecular cancer therapeutics. 2008; 7: 2233-40. doi:10.1158/1535-7163.MCT-08-0067.
18. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target. 2012; 20: 561-73. doi: 10.3109/1061186x.2012.702767.
19. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer chemotherapy and pharmacology. 2011; 68: 107-16. doi:10.1007/s00280-010-1462-2.
20. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol. 2002; 21: 25-9. doi: S0945-053x(01)00184-6Unsp 0945-053x/02/$Doi 10.1016/S0945-053x(01)00184-6.
21. Deed R, Rooney P, Kumar P, Norton JD, Smith J, Freemont AJ, et al. Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan. Int J Cancer. 1997; 71: 251-6. doi: 10.1002/(Sici)1097-0215(19970410)71:2<251::Aid-Ijc21>3.0.Co;2-J.
22. Pardue EL, Ibrahim S, Ramamurthi A. Role of hyaluronan in angiogenesis and its utility to angiogenic tissue engineering. Organogenesis. 2008; 4: 203-14.
23. Dufay Wojcicki A, Hillaireau H, Nascimento TL, Arpicco S, Taverna M, Ribes S, et al. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. Journal of controlled release. 2012; 162: 545-52. doi:10.1016/j.jconrel.2012.07.015.
24. Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer letters. 2013; 334: 338-45. doi:10.1016/j.canlet.2012.07.002.
25. Bragonzi A, Boletta A, Biffi A, Muggia A, Sersale G, Cheng SH, et al. Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs. Gene therapy. 1999; 6: 1995-2004. doi:10.1038/sj.gt.3301039.
26. Zou SM, Erbacher P, Remy JS, Behr JP. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. The journal of gene medicine. 2000; 2: 128-34. doi:10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W.
27. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene therapy. 1998; 5: 930-7. doi:10.1038/sj.gt.3300683.
28. Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene therapy. 1999; 6: 585-94. doi:10.1038/sj.gt.3300865.
29. Qian H, Yu J, Li Y, Wang H, Song C, Zhang X, et al. RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. Biology of the Cell. 2007; 99: 573-81. doi:10.1042/bc20060130.
30. Galan-Malo P, Vela L, Gonzalo O, Calvo-Sanjuan R, Gracia-Fleta L, Naval J, et al. Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold. Toxicol Appl Pharm. 2012; 258: 384-93. doi: 10.1016/j.taap.2011.11.021.
31. Lu XY, Zhang FY, Qin L, Xiao FY, Liang W. Polymeric micelles as a drug delivery system enhance cytotoxicity of vinorelbine through more intercellular accumulation. Drug Delivery. 2010; 17: 255-62. doi: 10.3109/10717541003702769.
32. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010; 31: 106-14. doi:10.1016/j.biomaterials.2009.09.030.
33. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Molecular therapy. 2010; 18: 1650-6. doi:10.1038/mt.2010.136.
34. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67: 4010-5. doi: 10.1158/0008-5472.Can-06-4180.
35. Takaishi S, Okumura T, Tu SP, Wang SSW, Shibata W, Vigneshwaran R, et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44. Stem Cells. 2009; 27: 1006-20. doi: 10.1002/Stem.30.
36. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, et al. Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers. Plos One. 2009; 4. doi:10.1371/Journal.Pone.0008377.
37. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012; 30: 2100-13. doi:10.1002/stem.1193.
38. Cortes-Dericks L, Froment L, Boesch R, Schmid R, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH high CD44+ phenotype and sphere-forming capacity. BMC cancer. 2014; 14: 304. doi:10.1186/1471-2407-14-304.
39. El-Khattouti A, Selimovic D, Haikel Y, Megahed M, Gomez CR, Hassan M. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer letters. 2014; 343: 123-33. doi:10.1016/j.canlet.2013.09.024.
40. Gazzaniga P, Cigna E, Panasiti V, Devirgiliis V, Bottoni U, Vincenzi B, et al. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. European journal of surgical oncology. 2010; 36: 1211-4. doi:10.1016/j.ejso.2010.05.001.
41. Chua C, Zaiden N, Chong KH, See SJ, Wong MC, Ang BT, et al. Characterization of a side population of astrocytoma cells in response to temozolomide. Journal of neurosurgery. 2008; 109: 856-66. doi:10.3171/JNS/2008/109/11/0856.
42. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005; 5: 275-84. doi:10.1038/nrc1590.
43. Pan Y, Song QL, Lin YH, Lu N, Yu HM, Li XJ. GLB prevents tumor metastasis of Lewis lung carcinoma by inhibiting tumor adhesion actions. Acta pharmacologica Sinica. 2005; 26: 881-6. doi:10.1111/j.1745-7254.2005.00125.x.
44. Hu TS, Liu SR, Breiter DR, Wang F, Tang Y, Sun SH. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008; 68: 6533-40. doi: 10.1158/0008-5472.Can-07-6642.
45. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, et al. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes & cancer. 2010; 1: 908-16. doi:10.1177/1947601910388271.
46. Guo Y, Mantel C, Hromas RA, Broxmeyer HE. Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: Effects associated with Stat3/Survivin. Stem Cells. 2008; 26: 30-4. doi: 10.1634/stemcells.2007-0401.
47. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001; 20: 147-55. doi: 10.1038/sj.onc.1204062.
48. Balekar N, Katkam NG, Nakpheng T, Jehtae K, Srichana T. Evaluation of the wound healing potential of Wedelia trilobata (L.) leaves. J Ethnopharmacol. 2012; 141: 817-24. doi: 10.1016/j.jep.2012.03.019.
49. Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharmaceutica Sinica B. 2014; 4: 193-201. doi:10.1016/j.apsb.2014.03.001.
50. Shi S, Han L, Gong T, Zhang Z, Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew Chem Int Ed Engl. 2013; 52: 3901-5. doi:10.1002/anie.201208077.
51. Atlasi Y, Mowla SJ, Ziaee SAM, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007; 120: 1598-602. doi: 10.1002/Ijc.22508.
52. Audouy SAL, de Leij LFMH, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharmaceut Res. 2002; 19: 1599-605. doi: 10.1023/A: 1020989709019.
53. Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. Journal of controlled release: official journal of the Controlled Release Society. 2003; 91: 167-72.
54. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006; 107: 459-66. doi:10.1002/cncr.22035.
55. Zhang W, Shi Y, Chen Y, Hao J, Sha X, Fang X. The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials. 2011; 32: 5934-44. doi:10.1016/j.biomaterials.2011.04.075.
56. Shen J, Yin Q, Chen L, Zhang Z, Li Y. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials. 2012; 33: 8613-24. doi:10.1016/j.biomaterials.2012.08.007.